Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.65 |
| ▸ | HTR2A | P28223 | 2/20 | 0.65 |
| ▸ | HTR7 | P34969 | 2/20 | 0.65 |
| ▸ | HTR6 | P50406 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.62 |
| ▸ | HTR3B | O95264 | 2/20 | 0.62 |
| ▸ | HTR3A | P46098 | 2/20 | 0.62 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.62 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11100857 | 0.90 | ALDH1A1 (0.75) | HTR1AHTR2AHTR7HTR6ALDH1A1 | |
| SCHEMBL6714846 | 0.90 | ALDH1A1 (0.75) | HTR1AHTR2AHTR7HTR6ALDH1A1 | |
| SCHEMBL9646111 | 0.84 | ALDH1A1 (0.73) | HTR1AHTR2AHTR7HTR6ALDH1A1 | |
| SCHEMBL27875601 | 0.82 | HTR1A (0.71) | HTR1AHTR2AHTR7HTR6ALDH1A1 | |
| SCHEMBL29595602 | 0.82 | HTR3E (0.69) | HTR1AHTR2AHTR7HTR6ALDH1A1 | |
| SCHEMBL30407444 | 0.82 | HTR3E (0.69) | HTR1AHTR2AHTR7HTR6ALDH1A1 | |
| SCHEMBL26770369 | 0.82 | HTR3E (0.69) | HTR1AHTR2AHTR7HTR6ALDH1A1 | |
| SCHEMBL1822683 | 0.82 | HTR3E (0.69) | HTR1AHTR2AHTR7HTR6ALDH1A1 | |
| SCHEMBL11210900 | 0.81 | ALDH1A1 (0.69) | HTR1AHTR2AHTR7HTR6ALDH1A1 | |
| SCHEMBL1384498 | 0.81 | KCNH2 (0.65) | HTR1AHTR2AHTR7HTR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1832928-B | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2012-07-04 | — | — | CN | claimed |
| JP-4838121-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| EP-1641764-B1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | claimed |
| JP-2007521278-A | — | — | 2007-08-02 | — | — | JP | claimed |
| CN-1832928-A | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2006-09-13 | — | — | CN | claimed |
| EP-1641764-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | Novartis AG (CH) | 2006-04-05 | — | — | EP | claimed |
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MEREO BIOPHARMA 1 LIMINTED (GB) | 2005-03-03 | — | — | US | claimed |
| WO-2005009973-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-02-03 | — | — | WO | claimed |
| CN-1153763-C | Remedies/preventives for frequent urination/urinary incontinence and tropone derivatives | 日本化药株式会社 | 2004-06-16 | — | — | CN | disclosed |
| CN-1261347-A | Remedies/preventives for frequent urination/urinary incontinence and tropone derivatives | NIPPON KAYAKU KK (JP) | 2000-07-26 | — | — | CN | disclosed |
| US-5945421-A | TREATING PSYCHOSIS AND SCHIZOPHRENIA | WARNER-LAMBERT COMPANY (US) | 1999-08-31 | — | — | US | disclosed |
| US-5378690-A | Treatment of angiotensin induced hypertension | SANKYO COMPANY, LIMITED (JP) | 1995-01-03 | — | — | US | disclosed |
| EP-0274259-A2 | New renin-inhibitory oligopeptides, their preparaton and their use | Sankyo Company Limited (JP) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | HTR1A 2661/4885HTR2A 2938/4885HTR7 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.